Drug name - Gemtesa

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8653260 UROVANT Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
Apr, 2029

(6 years from now)

US8247415 UROVANT Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists
Dec, 2030

(8 years from now)

CN102056917A UROVANT Hydroxymethyl Pyrrolidines As [Beta]3 Adrenergic Receptor Agonists
Apr, 2029

(6 years from now)

CN102391255B UROVANT Hydroxymethyl Pyrrolidine As 3 Adrenergic Receptor Agonists
Apr, 2029

(6 years from now)

CN102391255A UROVANT Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonist
Apr, 2029

(6 years from now)

CN102056917B UROVANT Hydroxymethyl Pyrrolidine As 3 Adrenergic Receptor Agonists
Apr, 2029

(6 years from now)

IN201005984P4 UROVANT Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonists
Apr, 2029

(6 years from now)

IN281652B UROVANT Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonists
Apr, 2029

(6 years from now)

EP2276756B1 UROVANT Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonists
Apr, 2029

(6 years from now)

EP2276756A1 UROVANT Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonists
Apr, 2029

(6 years from now)

EP2276756B8 UROVANT Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonists
Apr, 2029

(6 years from now)

EP2276756B9 UROVANT Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonists
Apr, 2029

(6 years from now)

Drugs and Companies using VIBEGRON ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
75MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.